FLT3-IN-40

FLT3-IN-40 (compound 1) potently inhibits MV4-11 cell proliferation with an IC₅₀ of 0.002 nM, exhibiting a gradual, biphasic dose-response profile^[1].
FLT3-IN-40 is an ATP-competitive type-I FLT3 inhibitor, inhibiting purified FLT3 kinase with an IC₅₀ of 16.26 nM and MV4-11 cellular FLT3 pathway signaling with an IC₅₀ of 0.80 nM for p-ERK inhibition^[1].
FLT3-IN-40 inhibits Molm14 cell proliferation with an IC₅₀ of 1.42 nM, and has much weaker antiproliferative activity against K562 (IC₅₀ 1583 nM) and Ba/F3 (IC₅₀ 8467 nM) cells lacking FLT3 activating mutations^[1].
FLT3-IN-40 (1 pM-10 nM; 72 h) induces minimal apoptosis in MV4-11 cells at picomolar concentrations, but triggers significant early (17.3%) and late (10.3%) apoptosis at 10 nM following 72 h of treatment^[1].
FLT3-IN-40 (1 pM-10 nM; 72 h) induces a moderate G₁ phase stabilization in MV4-11 cells at picomolar concentrations^[1].
FLT3-IN-40 exhibits high kinase selectivity, with strong binding only to FLT3 among the 96 kinases tested at 1 nM and 10 nM concentrations^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.